Mayukh Sukhatme Buys Shares in Roivant Sciences
Roivant Sciences' President & CIO, Mayukh Sukhatme, purchased 500,000 shares.
Key Points
- Mayukh Sukhatme, President & CIO of Roivant Sciences, bought 500,000 shares at $3.85 each on June 25, 2026.
- Roivant Sciences trades on NasdaqGS with a market cap of $24.5 billion and a 52-week high of $34.68.
- Analysts maintain a strong buy consensus with a mean target price of $39.04 for Roivant Sciences.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mayukh Sukhatme, the President and Chief Investment Officer of Roivant Sciences Ltd., made a significant purchase of the company's stock. On June 25, 2026, Sukhatme bought 500,000 shares of Roivant Sciences, which trades on the NasdaqGS under the ticker ROIV. The shares were acquired at an average price of $3.85 each, amounting to a total transaction value of approximately $1.93 million. This insider activity was not conducted under a pre-arranged trading plan.
Insider Buying and Selling at Roivant Sciences Ltd.
In addition to the purchase, Mayukh Sukhatme engaged in several sales transactions. On June 26, 2026, Sukhatme sold 500,000 shares at an average price of $34.08. Another sale of 500,000 shares took place on June 25, 2026, at $34.13 per share. These sales were also not part of a planned trading strategy.
Other Institutional Activity in Roivant Sciences
Institutional investors have been actively trading Roivant Sciences shares. FMR LLC increased its holdings by 12,201,789 shares, bringing its total to 77,981,253 shares, valued at approximately $2.16 billion. Meanwhile, Morgan Stanley reduced its position by 6,531,228 shares, ending with 51,828,325 shares worth about $1.44 billion. BlackRock, Inc. added 3,083,785 shares, totaling 44,254,260 shares valued at $1.23 billion. UBS Group AG also increased its stake by 4,228,680 shares, reaching 22,619,472 shares with a value of $626.6 million. Vanguard Capital Management LLC opened a new position with 20,680,572 shares valued at $572.9 million.
Roivant Sciences Ltd. Stock Up 0.1%
As of Tuesday, shares of Roivant Sciences were trading near $34.07. The company, with a market cap of $24.5 billion, operates in the biotechnology sector. Roivant has a forward P/E ratio of -21.85, indicating that it is not currently profitable. The stock's beta is 1.137, suggesting moderate volatility compared to the market. It has traded between $10.71 and $34.68 over the past 52 weeks, with its 50-day moving average at $29.56 and the 200-day moving average at $24.06. The company's financial health is reflected in its strong current ratio of 18.37 and a quick ratio of 17.999.
$ROIV stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Several analysts have maintained their ratings for Roivant Sciences. On May 26, 2026, Guggenheim maintained a "buy" rating with a price target of $36. Citigroup and TD Cowen also maintained "buy" ratings with targets of $42 and $41, respectively, on May 21, 2026. The stock has a strong buy consensus with an average target price of $39.04, based on 12 analyst opinions.
About Roivant Sciences
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom. Founded in 2014, the company focuses on developing and commercializing medicines and technologies. It operates in the biotechnology industry with a range of clinical product candidates targeting autoimmune and cardiopulmonary diseases. Roivant is led by CEO Matthew Gline and employs 721 people.
Bottom Line
The recent insider purchase by Mayukh Sukhatme highlights confidence in Roivant Sciences' prospects. Investors often track insider transactions for potential insights into a company's future. It's important to note that these transactions reflect past actions and may not indicate future performance.
Get Roivant Sciences Ltd. alerts
New 13F filings, insider trades, and analyst moves on $ROIV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.